KEITH BERGER, M.D.; RICHARD W. McCALLUM, M.D.
Nifedipine acts by inhibiting the slow transmembrane calcium flux responsible for electromechanical coupling in cardiac and smooth muscle (1, 2). Clinical trials have shown nifedipine to be effective and safe in treating coronary vasospasm (3-5). A European study suggests that nifedipine improves smooth muscle function in esophageal motility disorders, such as achalasia and diffuse esophageal spasm (6). We report the case of a patient with "vigorous" achalasia, who, refractory to all medical therapy, had a dramatic subjective and objective response to oral nifedipine.
The patient is a 63-year-old white man with a well-documented and long-standing history of atherosclerotic cardiovascular disease.
BERGER K, McCALLUM RW. Nifedipine in the Treatment of Achalasia. Ann Intern Med. ;96:61–62. doi: 10.7326/0003-4819-96-1-61
Download citation file:
Published: Ann Intern Med. 1982;96(1):61-62.
Esophageal Disorders, Gastroenterology/Hepatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use